DRI Healthcare exercises put option for US$178 million
DRI Healthcare Trust exercised a put option on its EKTERLY royalty right for approximately US$178 million, triggered by Chiesi Group's acquisition of KalVista Pharmaceuticals. Payment is expected by mid-August. The proceeds will be redeployed into the biopharmaceutical sector.
*this image is generated using AI for illustrative purposes only.
DRI Healthcare Trust has exercised its contractual put option regarding its royalty participation right in EKTERLY for a total net repurchase price of approximately US$178 million. The exercise follows the completion of Chiesi Group's acquisition of KalVista Pharmaceuticals on June 11, 2026. DRI Healthcare expects to receive the payment no later than mid-August.
The transaction allows DRI Healthcare to crystallize an attractive return for its unitholders. The proceeds are expected to be redeployed into the biopharmaceutical industry to generate long-term value. This marks the outcome of DRI Healthcare's first pre-approval transaction.
Ali Hedayat, Chief Executive Officer of DRI Healthcare, stated that exercising the put option at this juncture allows the company to crystallize an attractive return. He added that the proceeds reflect the quality of the company's underwriting. Navin Jacob, Chief Investment Officer of DRI Healthcare, noted that the firm looks forward to redeploying the proceeds into the biopharmaceutical industry.
Transaction Details
| Detail | Description |
|---|---|
| Asset | EKTERLY (sebetralstat) royalty participation right |
| Put Price | Approximately US$178 million |
| Trigger Event | Completion of Chiesi Group's acquisition of KalVista Pharmaceuticals |
| Expected Payment Date | No later than mid-August |
DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since its founding in 1989, the company has deployed more than $3.0 billion, acquiring more than 75 royalties on 50-plus drugs. DRI Healthcare's units are listed and trade on the TSX in Canadian dollars under the symbol "DHT.UN" and in U.S. dollars under the symbol "DHT.U".
What specific areas within the biopharmaceutical industry is DRI Healthcare targeting for redeployment of the $178 million proceeds?
How will the successful outcome of this first pre-approval transaction influence DRI Healthcare's strategy for future early-stage investments?
What impact will this liquidity event have on DRI Healthcare's distribution policy for unitholders in the upcoming quarters?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
